Skip to main content

Ischemic Stroke clinical trials at UCSD

3 in progress, 1 open to eligible people

Showing trials for
  • Sleep for Stroke Management and Recovery Trial

    open to eligible people ages 18 years and up

    The purpose of this study is to determine whether treatment of obstructive sleep apnea (OSA) with positive airway pressure starting shortly after acute ischemic stroke or high risk TIA (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event, and (2) improves stroke outcomes at 3 months in patients who experienced an ischemic stroke.

    La Jolla, California and other locations

  • Multi-arm Optimization of Stroke Thrombolysis

    Sorry, in progress, not accepting new patients

    The primary efficacy objective of the MOST trial is to determine if argatroban (100µg/kg bolus followed by 3µg/kg per minute for 12 hours) or eptifibatide (135µg/kg bolus followed by 0.75µg/kg/min infusion for two hours) results in improved 90-day modified Rankin scores (mRS) as compared with placebo in acute ischemic stroke (AIS) patients treated with standard of care thrombolysis (0.9mg/kg IV rt-PA or 0.25mg/kg IV tenecteplase or TNK) within three hours of symptom onset. Patients may also receive endovascular thrombectomy (ET) per usual care. Time of onset is defined as the last time the patient was last known to be well.

    La Jolla, California and other locations

  • Strategy for Improving Stroke Treatment Response

    Sorry, not currently recruiting here

    SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alpha-2 antiplasmin (a2-AP), in acute ischemic stroke.

    La Jolla, California and other locations

Our lead scientists for Ischemic Stroke research studies include .

Last updated: